澳华内镜(688212) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥162,282,968.92, representing a year-on-year increase of 10.37%[4] - The total profit for the period was -¥32,443,751.20, a decrease of 199.90% compared to the same period last year[4] - The net profit attributable to shareholders was -¥15,327,234.69, down 148.44% year-on-year[4] - The basic earnings per share for the period was -¥0.12, a decrease of 150.00% year-on-year[4] - The diluted earnings per share for the period was also -¥0.12, reflecting a 150.00% decline compared to the same period last year[4] - Total operating revenue for the first three quarters of 2025 was CNY 422,626,267.10, a decrease of 15.6% compared to CNY 500,553,520.06 in the same period of 2024[20] - The company reported a net loss of CNY 55,905,406.41 for the first three quarters of 2025, compared to a net profit of CNY 36,958,353.67 in the same period of 2024[22] - Operating profit for the first three quarters of 2025 was CNY -84,182,421.89, a significant decline from CNY 30,568,123.68 in 2024[21] - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY -0.42, compared to CNY 0.28 in the same period of 2024[22] - The total comprehensive income for the first three quarters of 2025 was CNY -67,951,341.30, compared to CNY 35,563,906.33 in 2024, indicating a negative shift[33] Research and Development - Research and development expenses totaled ¥39,796,629.50, an increase of 54.42% compared to the same period last year, accounting for 24.52% of operating revenue[5] - The company reported a significant increase in R&D investment as part of its long-term strategic initiatives, which has temporarily raised expense ratios[9] - Research and development expenses remained stable at CNY 113,605,753.86, compared to CNY 113,108,128.27 in the previous year[21] - The company's research and development expenses for the first three quarters of 2025 were CNY 115,029,853.81, slightly down from CNY 117,707,540.36 in 2024, reflecting a focus on maintaining R&D investment[32] Assets and Liabilities - The total assets at the end of the period were ¥1,826,626,179.89, reflecting a 4.46% increase from the end of the previous year[5] - Total current assets as of September 30, 2025, amount to ¥957,088,840.04, a decrease from ¥992,858,871.93 as of December 31, 2024[15] - The company's total equity decreased to CNY 1,207,126,914.47 from CNY 1,345,530,786.40 year-over-year[30] - Total liabilities rose to CNY 566,516,917.74, compared to CNY 368,197,409.69, reflecting an increase of 53.8%[17] - Total assets increased to CNY 1,826,626,179.89, up from CNY 1,748,676,638.82, indicating growth in the company's asset base[17] - The company's equity attributable to shareholders decreased to CNY 1,245,498,643.09 from CNY 1,366,055,677.44, a decline of 8.8%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,549[12] - The largest shareholder, Gu Xiaozhou, holds 21,740,500 shares, representing 16.14% of total shares[13] - The second largest shareholder, Gu Kang, holds 16,950,200 shares, representing 12.59% of total shares[13] - The company has no significant changes in the top 10 shareholders due to margin trading activities[13] Cash Flow - Cash inflow from operating activities for the first three quarters of 2025 was CNY 544,196,815.48, a slight increase from CNY 528,105,962.51 in the same period of 2024[25] - Net cash outflow from operating activities was CNY -98,694,502.97, improving from CNY -137,907,116.60 year-over-year[25] - Cash inflow from investment activities increased significantly to CNY 744,302,144.95 in 2025, compared to CNY 339,633,242.06 in 2024[26] - Net cash flow from investment activities was CNY 17,160,147.57, a turnaround from CNY -11,990,148.86 in the previous year[26] - Cash inflow from financing activities rose to CNY 442,017,678.34, up from CNY 110,525,317.50 in 2024[26] - Net cash flow from financing activities was CNY 148,073,526.96, compared to CNY 50,113,987.87 in the same period last year[26] Other Financial Metrics - The company's cash and cash equivalents at the end of the period were CNY 317,327,628.17, up from CNY 144,940,689.86 in the previous year[26] - The company's financial expenses in 2025 included interest expenses of CNY 4,447,934.20, compared to CNY 773,484.38 in 2024, indicating an increase in borrowing costs[32] - Deferred tax assets increased significantly to CNY 75,214,162.80 from CNY 44,840,115.68, indicating a potential future tax benefit[17]